Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

The use of bisphosphonates, particularly risedronate, in patients with osteoporosis is linked to a higher risk for acute angle closure but not open-angle glaucoma. Researchers conducted a ...

In another study of osteoporosis, actual adherence to a bisphosphonate regimen was found to be very low, with approximately half of patients discontinuing therapy within the first one to two years.

SEATTLE -- Risk of death was lower in the years after a bisphosphonate was started following a fracture rather than denosumab (Prolia), a target trial emulation found. In adults ages 50 and older who ...

The unprecedented coronavirus disease 2019 (COVID-19) pandemic facilitated the rapid development and subsequent deployment of several novel and highly effective vaccines. However, the role of ...